Assessing Amadeus IT Group (BME:AMS) Valuation After Recent Subtle Share Price Shifts

If you have been following Amadeus IT Group (BME:AMS), you might have noticed its latest share price shifts have caught the eye of investors looking for signs of opportunity or risk. While there has been no big headline announcement or news event driving the most recent moves, the stock’s subtle momentum changes offer plenty to dissect, especially for those weighing the balance between optimism and caution in the current environment.

Putting the latest fluctuations into context, Amadeus IT Group has delivered a total return of 12% over the past year, with short-term performance taking a backseat to steady multi-year growth. A quick glance at recent momentum shows the stock has cooled somewhat in the past month. Even so, Amadeus’s annual and three-year gains continue to outpace much of its sector, and previous earnings results showed positive revenue and net income growth.

After this year’s measured rise, is Amadeus IT Group undervalued at today’s levels, or are investors already pricing in all of its future growth?

Advertisement

Most Popular Narrative: 11.2% Undervalued

According to the most widely followed narrative, Amadeus IT Group is considered undervalued by 11.2% at current share price levels. This suggests there may be room for further upside if optimistic assumptions hold true.

Continued global growth in travel, particularly in Asia Pacific (10% PB growth) and steady recovery post-COVID, suggests persistent expansion of Amadeus's addressable markets and transaction volumes. This supports longer-term top-line (revenue) growth as travel demand rises globally.

Curious what’s behind the bullish price target? The fair value is based on a blend of robust travel sector growth and ambitious financial targets. Which future growth rates, margin improvements, and premium profit multiples do analysts believe make Amadeus attractive? Discover the full narrative to see what could set this stock apart.

Result: Fair Value of €77.81 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent high R&D spending and any downturn in global travel could quickly challenge these optimistic assumptions and limit the anticipated growth of Amadeus.

Find out about the key risks to this Amadeus IT Group narrative.

Another View: Market Ratios Tell a Different Story

Looking at Amadeus IT Group through the lens of market price ratios provides a less optimistic perspective. These ratios suggest the stock may be trading above fair value, raising fresh questions about the company's current share price. Which verdict seems more convincing?

See what the numbers say about this price — find out in our valuation breakdown.
BME:AMS PE Ratio as at Sep 2025
BME:AMS PE Ratio as at Sep 2025
Stay updated when valuation signals shift by adding Amadeus IT Group to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Amadeus IT Group Narrative

If you have a different perspective or want to take a deeper dive into Amadeus IT Group's numbers, you can assemble your own outlook in just a few minutes using our interactive tools. Do it your way.

A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Amadeus IT Group.

Looking for more investment ideas?

Seize the advantage today by using Simply Wall Street's screeners. Don't let game-changing opportunities pass you by while others move ahead.

  • Unlock future trends by scanning for innovation leaders in the AI space with AI penny stocks and see who is pushing technology boundaries in the market.
  • Maximize your potential income and stability by checking out reliable opportunities offering robust payouts through dividend stocks with yields > 3%.
  • Get ahead of the curve by pinpointing companies currently trading for less than they're worth with undervalued stocks based on cash flows, and position yourself for value-driven growth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About BME:AMS

Amadeus IT Group

Operates as a transaction processor for the travel and tourism industry in Europe, Central and South America, the Middle East, Africa, and Asia Pacific.

Undervalued average dividend payer.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0